

## S

### InVivoMAb Anti-SARS-CoV-2 RBD (JN.1) Neutralizing (Iv0222)

<b>Catalog No.</b>	VVV00312A VVV00312B	<b>Quantity:</b>	100 µg 1.0 mg
<b>Alternate Names:</b>	Spike glycoprotein, S glycoprotein, Spike protein S1, Receptor-Binding Domain, RBD, JN.1, SARS-CoV-2 (2019-nCoV)		
<b>Description:</b>	Neutralizing human monoclonal antibody (clone Iv0222) which targets SARS-CoV-2 (2019-nCoV) Receptor Binding Domain (JN.1) Protein		
<b>UniProt ID (target):</b>	P0DTC2		
<b>Source:</b>	Mammalian cells		
<b>Specificity:</b>	SARS-CoV-2 (2019-nCoV) Spike glycoprotein RBD		
<b>Isotype:</b>	Human IgG1 kappa		
<b>Clone:</b>	Iv0222		
<b>Purification:</b>	Protein A or G affinity chromatography		
<b>Purity:</b>	> 95% by SDS-PAGE		
<b>Formulation:</b>	Sterile-filtered 0.01M PBS, pH 7.4		
<b>Endotoxin:</b>	< 0.01 EU/µg		
<b>Concentration:</b>	1.0 mg/ml, lot specific		
<b>Applications:</b>	Functional studies, Neutralizing, ELISA EC <sub>50</sub> = 257.9 ng/ml, binding to SARS-CoV-2 RBD (JN.1) protein		
<b>Storage &amp; Stability:</b>	Store at 2-8°C for immediate use within 1-2 weeks or aliquot the stock solution and store at -20°C to -80°C up to 1 year. <b>Avoid repeated freeze/thaw cycles.</b>		

NOT FOR HUMAN USE. FOR RESEARCH ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE.